Publications by authors named "Nada Rifi"

Claim this Profile
P
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Hannah Le, Josh Coulter, Ken Culver, Joseph C Cappelleri, Nada Rifi

Lung Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn, Nada Rifi

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.
Dipesh Uprety, Devin Abrahami, Zachary A Marcum, Benjamin Li, Angela Sang, Nada Rifi

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
Ernest Nadal, Nada Rifi, Sarah Kane, Sokhna Mbacke, Lindsey Starkman

Lung Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis